Видео ютуба по тегу Trial: Surpass Et

Current treatment approaches in ET and an insight into the SURPASS-ET trial
Current treatment approaches in ET and an insight into the SURPASS-ET trial
Dr. Ruben Mesa on the SURPASS-ET Trial and Unmet Needs in Essential Thrombocythemia
Dr. Ruben Mesa on the SURPASS-ET Trial and Unmet Needs in Essential Thrombocythemia
Topline results from the SURPASS-ET trial: ropeginterferon alfa-2b versus anagrelide in ET
Topline results from the SURPASS-ET trial: ropeginterferon alfa-2b versus anagrelide in ET
SURPASS ET: ropeginterferon alfa-2b vs anagrelide for second-line essential thrombocythemia
SURPASS ET: ropeginterferon alfa-2b vs anagrelide for second-line essential thrombocythemia
The SURPASS-ET study: evaluating novel treatment approaches in ET
The SURPASS-ET study: evaluating novel treatment approaches in ET
SURPASS ET: ropeginterferon versus anagrelide as second line therapy in essential thrombocythemia
SURPASS ET: ropeginterferon versus anagrelide as second line therapy in essential thrombocythemia
Dr. Masarova discusses SURPASS-ET study at #eha2025
Dr. Masarova discusses SURPASS-ET study at #eha2025
Comparing ropeginterferon alfa-2b to anagrelide in ET: topline results of SURPASS-ET
Comparing ropeginterferon alfa-2b to anagrelide in ET: topline results of SURPASS-ET
SURPASS ET: P1101 in essential thrombocythemia
SURPASS ET: P1101 in essential thrombocythemia
Tirzepatide vs Dulaglutide for Cardiovascular Outcomes (SURPASS-CVOT) | NEJM | Med Journal Club
Tirzepatide vs Dulaglutide for Cardiovascular Outcomes (SURPASS-CVOT) | NEJM | Med Journal Club
EXCEED-ET: ropeginterferon alfa-2b in adults with essential thrombocythemia
EXCEED-ET: ropeginterferon alfa-2b in adults with essential thrombocythemia
Тирзепатид демонстрирует пользу для почек при сахарном диабете 2 типа: анализ исследований SURPASS
Тирзепатид демонстрирует пользу для почек при сахарном диабете 2 типа: анализ исследований SURPASS
AHA 25: SURPASS-CVOT: тирзепатид против дулаглутида при сердечной недостаточности у пациентов с с...
AHA 25: SURPASS-CVOT: тирзепатид против дулаглутида при сердечной недостаточности у пациентов с с...
What's new in essential thrombocythemia in 2025?
What's new in essential thrombocythemia in 2025?
Специальный выпуск: Исследования сердечно-сосудистых исходов – происхождение и перспективы
Специальный выпуск: Исследования сердечно-сосудистых исходов – происхождение и перспективы
Does Mounjaro Prevent Heart Attacks? Docs React to New Study
Does Mounjaro Prevent Heart Attacks? Docs React to New Study
Анализ результатов исследования SURMOUNT-4 #тирзепатида #привязанногозепа #ожирение #врач
Анализ результатов исследования SURMOUNT-4 #тирзепатида #привязанногозепа #ожирение #врач
Lucia Masarova, MD, Discusses EXCEED-ET Trial Design, Enrollment Process
Lucia Masarova, MD, Discusses EXCEED-ET Trial Design, Enrollment Process
Upcoming trials and novel agents in MPNs
Upcoming trials and novel agents in MPNs
Adaptimmune Therapeutics kicks off SURPASS clinical trial to target solid tumor cancers
Adaptimmune Therapeutics kicks off SURPASS clinical trial to target solid tumor cancers
Recent advances and trial updates in MPNs: insights from EHA 2025
Recent advances and trial updates in MPNs: insights from EHA 2025